SCHEMBL6487935

SCHEMBL6487935

CC[C@](O)(c1ccc(OC)cc1)[C@@H](O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KIF11 P52732 4/20 0.45
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
ALOX15 P16050 1/20 0.42
APEX1 P27695 1/20 0.42
MAPK1 P28482 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
PKM P14618 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6872397 1.00 LDHA (0.46) LDHAMEN1KMT2AKIF11ALDH1A1
SCHEMBL7015543 1.00 LDHA (0.46) LDHAMEN1KMT2AKIF11ALDH1A1
SCHEMBL606118 0.82 KIF11 (0.44) KMT2AKIF11LMNACYP1A2MAPT
SCHEMBL7540245 0.81 LDHA (0.46) LDHAMEN1KMT2AKIF11ALDH1A1
SCHEMBL27839176 0.78 LDHA (0.45) LDHAKIF11ALDH1A1LMNAALOX15
SCHEMBL4653290 0.76 LDHA (0.50) LDHAKIF11ALDH1A1LMNAALOX15
SCHEMBL10980312 0.75 ALDH1A1 (0.44) MEN1KMT2AALDH1A1LMNAALOX15
SCHEMBL27866045 0.75 PPARG (0.47) LDHAMEN1KMT2AKIF11ALDH1A1
SCHEMBL8457734 0.74 KIF11 (0.54) LDHAMEN1KMT2AKIF11ALDH1A1
SCHEMBL29226417 0.73 ALDH1A1 (0.46) LDHAKMT2AKIF11ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881839-B2 Process for preparing diltiazem using a heterogeneous trifunctional catalyst COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-04-19 US claimed
US-20040127704-A1 Process for preparing diltiazem using a heterogeneous trifunctional catalyst COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-07-01 US claimed
US-6881839-B2 Process for preparing diltiazem using a heterogeneous trifunctional catalyst COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-04-19 US disclosed
WO-2004058734-A1 PROCESS FOR PREPARING DILTIAZEM USING A HETEROGENEOUS TRIFUNCTIONAL CATALYST COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-07-15 WO disclosed
US-20040127704-A1 Process for preparing diltiazem using a heterogeneous trifunctional catalyst COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127704-A1 Process for preparing diltiazem using a heterogeneous trifunctional catalyst CYP2W1, INMT, TST LDHA 1660/4885MEN1 4650/4885KMT2A 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.